Last update 01 Apr 2025

Veligrotug

Overview

Basic Info

Drug Type
Monoclonal antibody
Synonyms
泽纳001, AVE 1642, VRDN 001
+ [5]
Target
Action
antagonists
Mechanism
IGF-1R antagonists(Insulin-like growth factor I receptor antagonists)
Active Indication
Originator Organization
Inactive Organization
Drug Highest PhasePhase 3
First Approval Date-
Regulation-
Login to view timeline

Structure/Sequence

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Graves OphthalmopathyPhase 3
United States
03 Dec 2021
Graves OphthalmopathyPhase 3
Australia
03 Dec 2021
Graves OphthalmopathyPhase 3
Canada
03 Dec 2021
Graves OphthalmopathyPhase 3
France
03 Dec 2021
Graves OphthalmopathyPhase 3
Germany
03 Dec 2021
Graves OphthalmopathyPhase 3
Italy
03 Dec 2021
Graves OphthalmopathyPhase 3
Netherlands
03 Dec 2021
Graves OphthalmopathyPhase 3
Spain
03 Dec 2021
Graves OphthalmopathyPhase 3
Turkey
03 Dec 2021
Graves OphthalmopathyPhase 3
United Kingdom
03 Dec 2021
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
188
rxgwmiyrrf(hdwecqnkbo) = pnzptfkelk tynhemiwqj (vopgcdlshs )
Met
Positive
16 Dec 2024
Placebo
rxgwmiyrrf(hdwecqnkbo) = radiwawvea tynhemiwqj (vopgcdlshs )
Met
Phase 3
113
Veligrotug (VRDN-001)
ivefzywtww(tduoicjtlm) = ixxsmhyfjd rumgawyufg (yclyumzabe )
Met
Positive
10 Sep 2024
Placebo
ivefzywtww(tduoicjtlm) = wahjhwkbrx rumgawyufg (yclyumzabe )
Met
Phase 1/2
8
VRDN-001 10 mg/kg
ataovxbxbw(pfjthrbzhx) = One case of transient hearing impairment that resolved by next visit, with normal audiometry, was reported. No serious AEs, hyperglycemia, or infusion reactions occurred. eulzlzvaik (servqteihx )
Positive
25 Apr 2023
Placebo
Phase 1/2
Graves Ophthalmopathy
IGF-1 receptor
8
zexcnfzewe(iptwsygyvb) = AEs were mostly mild, with no severe or serious AEs reported alkyzwuyjr (mfigpwmver )
Positive
23 Apr 2023
Placebo
Phase 1/2
12
(10 mg/kg)
yxnndqnlal(adpnfeseef) = ydrecwcben owdzuolqlf (knmwuapoxz )
Positive
14 Nov 2022
(20 mg/kg)
yxnndqnlal(adpnfeseef) = wqoecamqtn owdzuolqlf (knmwuapoxz )
Phase 1/2
8
okirwrstjd(umkqjqqmsf) = fwjluodgjl fbtpmsvikl (quttzaxtij )
Positive
15 Aug 2022
Placebo
okirwrstjd(umkqjqqmsf) = accrqhjxzu fbtpmsvikl (quttzaxtij )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free